Skip to content

    Axsome Therapeutics (AXSM) stock price & financials

    View AXSM earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+63.3% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $104.76M
    $118.77M
    $121.46M
    $150.04M
    $170.99M
    +63.2%
    $196.00M
    +65.0%
    $191.20M
    +57.4%
    $218.38M
    +45.5%
    Strengthening
    Operating Profit
    -$62.62M
    -$72.62M
    -$56.98M
    -$36.71M
    -$46.11M
    +26.4%
    -$26.96M
    +62.9%
    -$63.36M
    -11.2%
    -$49.65M
    -35.2%
    Strengthening
    Net Profit
    -$64.60M
    -$74.91M
    -$59.41M
    -$47.97M
    -$47.23M
    +26.9%
    -$28.56M
    +61.9%
    -$64.54M
    -8.6%
    -$51.31M
    -7.0%
    Strengthening
    EPS
    $-1.34
    $-1.22
    $-0.97
    $-0.94
    +29.9%
    $-1.26
    -3.3%
    $-0.99
    -2.1%
    Stable
    Other Income
    Interest
    -$5.67M
    -$5.43M
    $5.26M
    -$4.09M
    -$3.38M
    +40.4%
    -$13.72M
    -152.8%
    $3.09M
    -41.2%
    -$3.20M
    +21.7%
    Weakening
    Depreciation
    Profit before Tax
    -$64.60M
    -$74.83M
    -$59.41M
    -$48.93M
    -$47.23M
    +26.9%
    -$28.13M
    +62.4%
    -$64.54M
    -8.6%
    -$51.19M
    -4.6%
    Strengthening
    MarginsOPM
    -59.8%
    -61.1%
    -46.9%
    -24.5%
    -27.0%
    +54.9%
    -13.8%
    +77.5%
    -33.1%
    +29.4%
    -22.7%
    +7.1%
    Strengthening
    Tax
    0.0%
    -0.1%
    0.0%
    2.0%
    0.0%
    -1.5%
    -1290.9%
    0.0%
    -0.3%
    -112.8%
    Weakening
    ReturnsROIC
    4.5%
    5.3%
    4.2%
    3.4%
    3.3%
    -26.9%
    2.0%
    -61.9%
    4.5%
    +8.6%
    3.6%
    +7.0%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$219.97M$183.88M$86.47M$200.84M$386.19M$315.35M$322.93M$319.85M
    Short-Term Investments
    Total Current Assets$15.22M$220.38M$184.02M$86.52M$245.64M$504.26M$485.06M$588.99M$656.57M
    Net PP&E$51.8K$30.6K$1.79M$944.0K$1.14M$7.62M$5.97M$21.42M$20.03M
    Goodwill$10.31M$12.04M$12.04M$12.04M$12.04M
    Intangibles$59.66M$53.29M$46.89M$40.52M$37.36M
    Total Assets$15.38M$220.55M$186.13M$87.79M$331.48M$588.24M$568.50M$689.80M$761.45M
    LiabilitiesTotal Current Liabilities$10.82M$24.49M$23.44M$23.07M$96.56M$138.85M$230.10M$378.84M$460.45M
    Short-Term Debt$3.29M$2.60M$0$70.00M$70.00M
    Long-Term Debt$3.62M$17.33M$48.32M$49.09M$94.26M$178.07M$180.71M$117.75M$117.96M
    Long-Term Leases$581.7K$7.04M$6.05M$23.18M$21.57M
    Total Liabilities$14.44M$41.83M$72.34M$72.15M$221.92M$397.26M$511.48M$601.51M$678.14M
    EquityCommon Stock & APIC$3.0K$3.7K$3.7K$3.8K$4.0K$5.0K$5.0K$5.0K$5.0K
    Retained Earnings-$107.55M-$175.90M-$278.80M-$409.20M-$596.33M-$835.57M-$1.12B-$1.31B-$1.42B
    Total Equity$937.9K$178.72M$113.79M$15.63M$109.56M$190.98M$57.02M$88.30M$83.30M
    HighlightsNet Cash / (Debt)$200.03M$134.64M$135.19M$131.89M

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$30.05M-$46.38M-$78.46M-$108.23M-$116.51M-$145.08M-$128.41M-$93.41M-$71.26M
    Cash from Investing-$32.7K-$16.1K-$45.9K-$308.0K-$53.70M-$582.0K-$270.0K-$480.0K-$700.0K
    Cash from Financing$10.03M$252.39M$42.41M$11.13M$284.58M$331.01M$57.84M$101.47M$88.79M
    SummaryCapital Expenditure-$32.7K-$16.1K-$45.9K-$308.0K-$702.0K-$582.0K-$270.0K-$480.0K-$700.0K
    Free Cash Flow-$30.09M-$46.39M-$78.50M-$108.53M-$117.21M-$145.66M-$128.68M-$93.89M-$71.96M
    FCF Margin-53.8%-33.4%-14.7%-9.3%

    Ratios